Definium Therapeutics (CIK 0001813814, formerly Mind Medicine (MindMed) Inc.) is a late-stage clinical company whose entire equity story now rests on one molecule: DT120, a pharmaceutically optimized orally disintegrating tablet of lysergide D-tartrate, the active form of LSD. The stock sits near 38 per share for a firm with no revenue. The accumulated deficit is 818.8 million. In short, the market is pricing a clinical record. At a market value of roughly 5.1 billion, the stock is a bet on a clinical record. Emerge in MDD and Voyage in GAD both reported positive Phase 3 topline data in 2026, and the Panorama readout in GAD lands in September, so the price embeds a high-probability commercial pathway for a monitored-session psychedelic.
The case against is the gap between topline data and a saleable drug. DT120 is built on a Schedule 1 controlled substance, so any approval path runs through DEA and state rescheduling, a restricted distribution and practitioner certification model, and pricing with no precedent in psychiatry. That gap, not the clinical data, is the real question for the equity. Two equity raises funded the company. The first came in late last year for 259 million. A follow-on of 700 million arrived in June, removing the near-term financing constraint. The equity base sits at 134.4 million shares. The 2022 financing warrants remain a liability. The base case is GAD approval around 2029. The bear case is a rescheduling stall, or a second Phase 3 disappointment that pulls the stock back toward prior levels.